uBiome: Ethical Lapse or Not?
By Judy Stone,
Scientific American
| 07. 25. 2013
uBiome’s CEO, Jessica Richman, seems to me to be a great saleswoman who also excels at sounding innocent and playing the misunderstood victim in the ethical controversy surrounding her company. I think this was well illustrated in her recent guest blog in Scientific American with Dr. Zachary Apte, co-founder and Chief Scientific Officer of uBiome. The picture is a little less rosy if you look back at the origins and history of the discussions about her company’s perceived ethical lapses.
I was intending to write about uBiome before this, as I was disturbed by Richman’s appearance at TEDMED. Admittedly, I was already put off by her telling twitter handle of “@venturejessica.” Her hubris was further evidenced by the title of her TEDMED talk, “Could a citizen scientist win a Nobel Prize?” Fortunately, her talk was a bit more restrained, though still touting the potential of her as yet untested product.
Richman and Apte’s recent blog has shown that they seem to have learned little from the heated discussions about uBiome. Their business is part of the UCSF’s Quantitative Biosciences Institute...
Related Articles
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Risa Cromer, The Conversation | 07.17.2026
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
Media coverage of recent developments in embryo gene editing might seem to suggest that gene-edited babies are close to becoming a reality. As tech billionaires eager to profit off of techno-eugenics invest in “designer baby” technologies, attempts to normalize heritable genome editing – which remains unsafe and raises significant ethical and societal concerns – are especially dangerous. It’s worth taking a closer look at these developments and what they mean, in a way that pushes back on narratives normalizing the...